Investigating how CD4+ T cells interact with cancer cells in melanoma treatment.
CD4+ T cells and neoantigens in melanoma immunotherapy.
This study is looking at how certain immune cells in your body can spot new targets in melanoma, a type of skin cancer, to help create better treatments that are tailored just for you, especially if current therapies aren't working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10993169 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CD4+ T cells in recognizing and responding to neoantigens in melanoma, a type of skin cancer. By utilizing advanced techniques like whole exome sequencing and computer-assisted prediction algorithms, the study aims to identify specific antigens that can be targeted for immunotherapy. The goal is to enhance the effectiveness of existing treatments, particularly for patients who do not respond to current therapies. Patients may benefit from personalized treatment strategies based on their unique tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with melanoma who have not responded to standard immunotherapy treatments.
Not a fit: Patients with non-melanoma cancers or those who have not been diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for melanoma patients, particularly those who currently do not respond to existing treatments.
How similar studies have performed: Previous research has shown promising results in using neoantigens for immunotherapy, indicating that this approach has potential for success.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Wang, Rongfu — University of Southern California
- Study coordinator: Wang, Rongfu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.